Neuregulin-1/erbB activities with focus on the susceptibility of the heart to anthracyclines

Table 3 Cardiac phenotypic modifications

Morphology	WT	KO	WTD	KOD
Young adult (1 mo)
Heart/body weight (mg/g)	5.2 ± 0.4	5.3 ± 0.6	5.2 ± 0.5	6.2 ± 0.8a
Body weight (g)	17.4 ± 2.0	17.3 ± 2.2	17.3 ± 2.0	17.2 ± 1.5
Adult (3 mo)
Heart/body weight (mg/g)	5.6 ± 0.6	7.0 ± 0.8d	5.4 ± 0.7	6.7 ± 0.8d
Body weight (g)	30.1 ± 2.5	30.3 ± 2.2	29.4 ± 2.2	28.4 ± 2.2
Cardiotoxic gene groups
Dilation (ratio)	-	3	1.8	2.8
Hypertrophy (ratio)	-	9.9	3.3	6.5
Damage (ratio)	-	3.7	3.7	3.6
Cell death/ necrosis (Ratio)	-	3.0	4.3	3.1
Measured activity
Caspase 3 (arbitrary units)	0.25 ± 0.17	0.44 ± 0.17	0.84 ± 0.09a	0.35 ± 0.07
Autophagic vacuolization (n°)	0.07 ± 0.1	0.35 ± 0.3	0.2 ± 0.2	2.4 ± 2.1a
Serum cTnI (mg/mL)	0.15 ± 0.1	3.6 ± 1.5	0.7 ± 0.2	14.5 ± 4.2a
LVDP (mmHg)	109.2 ± 7.1	42 ± 8.2a	94.5 ± 5.5	31.5 ± 5.4a
Tau ½	37.4 ± 1.9	38.1 ± 4.9	36.1 ± 3.1	34.6 ± 2.9

Morphological and biochemical modifications studied in the aggravated cardiotoxic condition of the doxorubicin-treated-ventricular specific erbB4-KO mouse model. Summary of hypertrophic-associated morphological changes determined in mouse at the age of 1 and 3 mo, group of differentially expressed genes clustered into a wide-range of cardiotoxic conditions, biochemical activities associated to cell death and of physiological systolic and diastolic parameters are represented as discussed in the text.

^aP < 0.05 vs WT,

^dP < 0.01 vs WT and WTD. WTD: Doxorubicin-treated wildtype; KOD: Doxorubicin-treated erbB4-KO; WT: Treated wildtype.